The patients’ scores on MetaSite Breast did not correlate with tumor size, nodal status or genetic signature, but it did serve as a reliable predictor of five-year disease recurrence among women with HR+ cancer who also tested negative for human epidermal growth factor receptor 2. Here, ERBB2 is linked to neoplasm.